EXPANDING OPTIONS FOR PATIENT CARE
The Pfizer Oncology Biosimilars Portfolio
Select any of the biosimilar products to access helpful resources that may benefit your practice. You'll find Prescribing Information and Important Safety Information, clinical data, and support on how to implement patient communications, benefits verification, medication ordering, and much more. Visit this site regularly to ensure you have the latest updates and newest resources as they are added.
An FDA-approved biosimilar*
to Neupogen® (filgrastim)1
Please see full Prescribing Information,
including Patient Information, and Instructions for Use, for NIVESTYM.
An FDA-approved biosimilar* to
Neulasta® (pegfilgrastim)2
Please see full Prescribing Information,
Patient Information, and Instructions for Use for NYVEPRIA.
An FDA-approved biosimilar* to Epogen®/Procrit® (epoetin alfa)3
Please see full Prescribing Information,
including BOXED WARNINGS,
Medication Guide, and Instructions for Use for RETACRIT.
An FDA-approved biosimilar*
to Rituxan® (rituximab)4
Please see full Prescribing Information,
including BOXED WARNINGS and
Medication Guide, for RUXIENCE.
An FDA-approved biosimilar*
to Herceptin® (trastuzumab)5
Please see full Prescribing Information,
including BOXED WARNINGS,
for TRAZIMERA.
An FDA-approved biosimilar*
to Avastin® (bevacizumab)6
Please see full Prescribing Information
for ZIRABEV.